Mauna Kea Technologies Appoints Claire Biot, Ph.D. To Board of Directors

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA,) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, announced today the appointment of Claire Biot, Ph.D., as an Independent Director, effective immediately. Dr Claire Biot is currently employed as Vice-President Life Science Industries at Dassault Systèmes, “the 3DEXPERIENCE Company.”

“On behalf of the Board, I am pleased to welcome Claire Biot to the Mauna Kea Technologies Board of Directors,” said Sacha Loiseau, Ph.D. Chairman and Founder of the Mauna Kea Technologies. “Claire not only has an exceptional mind but also an impressive leadership experience in the field of medical technologies, from a commercial and market access standpoint. Her current role at Dassault Systèmes gives her a unique and very interesting vantage point on Mauna Kea’s commercial growth opportunities. We very much look forward to her contribution.”

Claire Biot commented, “Mauna Kea Technologies has been at the forefront of medtech innovation for 20 years, developing one of the most interesting and versatile imaging platform now recognized as an important complement to leading robotics platform. I am thrilled to be joining Mauna Kea’s Board of Directors and to support the work of the leadership team as they continue to build the future of personalized medicine and optimized care, two topics which are very much aligned with our work at Dassault Systèmes.”

Claire Biot graduated from Ecole Polytechnique and earned a Ph.D. in Immuno-oncology at Institut Pasteur. Claire then became the Head of Division, Health Products Pricing and Reimbursement at the Ministry of Health in France, before becoming Managing Director of AGEPS, the Health Products and Technologies Central Agency at Greater Paris University Hospitals (AP-HP), with several missions including the procurement of health products and technologies for the 39 hospitals of the group (€1.6 billion annual budget). After 3 years at AGEPS, she joined Dassault Systèmes as Vice-President Life Sciences Industry, with the mission to develop Dassault Systèmes market share and revenue in Life Sciences and Healthcare.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product, Cellvizio®, has received clearance/approval for a wide range of applications in the United States and more than 40 countries around the World. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Disclaimer

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties including the risks set forth in the registration document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on July 12, 2019 under number D.19-0683 and available on the Company's website (www.maunakeatech.com), and to the development of economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any country.